Filtered By:
Condition: Bleeding
Management: Hospitals

This page shows you your search results in order of relevance. This is page number 19.

Order by Relevance | Date

Total 576 results found since Jan 2013.

One-Stop Hybrid Coronary Revascularization Versus Off-Pump Coronary Artery Bypass Grafting
Int Heart J. 2022;63(3):441-446. doi: 10.1536/ihj.21-705.ABSTRACTOne-stop hybrid coronary revascularization (HCR) is a promising revascularization strategy for treating multivessel coronary artery disease (MVCAD). However, its safety and feasibility remain controversial. Therefore, we introduced our experience with midterm follow-up of HCR in patients with MVCAD and compared it with conventional off-pump coronary artery bypass grafting (CABG).Patients with MVCAD undergoing one-stop HCR at Beijing Chaoyang Hospital between March 2018 and December 2020 were retrospectively enrolled. These patients were matched in a 1:2 ratio...
Source: International Heart Journal - June 1, 2022 Category: Cardiology Authors: Yanyan Li Zhiyong Zhang Jie Gao Chuang Li Kuibao Li Pixiong Su Lefeng Wang Source Type: research

My debilitating endometriosis symptoms – Kate ’ s story
Hi, I’m Kate, 39, married with no children. I had always suffered from heavy and painful periods but this had mostly been managed by taking the combined pill. My periods remained heavy and I suffered from some flooding but this was manageable with planning! Approximately 7 years ago my periods became worse and I started to experience more symptoms such as regular and frequent abdominal pain, random bleeding, bloating, very painful intercourse and things just didn’t feel right. Anyway, I went to the Dr’s who straight away suggested that it sounded like I had endometriosis and referred me to a consultant. A...
Source: The Hysterectomy Association - March 1, 2017 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Health endometriosis hysterectomy stories Source Type: news

Stand-Alone Left Atrial appendage occlusion for throMboembolism prevention in nonvalvular Atrial fibrillatioN DiseasE Registry (SALAMANDER): protocol for a prospective observational nationwide study
Introduction Atrial fibrillation (AF) is a prevalent disease considerably contributing to the worldwide cardiovascular burden. For patients at high thromboembolic risk (CHA2DS2-VASc ≥3) and not suitable for chronic oral anticoagulation, owing to history of major bleeding or other contraindications, left atrial appendage occlusion (LAAO) is indicated for stroke prevention, as it lowers patient’s ischaemic burden without augmentation in their anticoagulation profile. Methods and analysis Stand-Alone Left Atrial appendage occlusion for throMboembolism prevention in nonvalvular Atrial fibrillatioN DiseasE Registry (S...
Source: BMJ Open - September 21, 2022 Category: General Medicine Authors: Kowalewski, M., Wanha, W., Litwinowicz, R., Kołodziejczak, M., Pasierski, M., Januszek, R., Kuzma, Łukasz, Grygier, M., Lesiak, M., Kapłon-Cieslicka, A., Reczuch, K., Gil, R., Pawłowski, T., Bartus, K., Dobrzycki, S., Lorusso, Tags: Open access, Cardiovascular medicine Source Type: research

Effects of a Pharmacist-Led Educational Interventional Program on Electronic Monitoring-Assessed Adherence to Direct Oral Anticoagulants: A Randomized, Controlled Trial in Patients with Nonvalvular Atrial Fibrillation
In this study, the selection of DOACs was not randomized, and the lack of assessment of the association between adherence to DOACs and clinical outcomes was a limitation. Japan Registry of Clinical Trials (jRCT) indentifier: jRCTs031180142. (Clin Ther. 2022;44:XXX-XXX) © 2022 Elsevier Inc.PMID:36244853 | DOI:10.1016/j.clinthera.2022.09.011
Source: Clinical Therapeutics - October 16, 2022 Category: Drugs & Pharmacology Authors: Tsuyoshi Shiga Toshimi Kimura Noritoshi Fukushima Yuji Yoshiyama Kazunori Iwade Fumiaki Mori Yoichi Ajiro Shoji Haruta Yuichiro Yamada Emi Sawada Nobuhisa Hagiwara SMAAP-AF Investigators Source Type: research

Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research